Tag: covid

1. The initial doses of the Pfizer and AstraZeneca vaccines were 91% and 88% efficacious in reducing COVID-19 hospitalizations one month after vaccination. 2. Combined vaccine efficacy of the Pfizer and AstraZeneca in preventing hospital admission due to COVID-19 among those aged 80 years and older was approximately 83%. Evidence Rating...
1. Compared to usual care, fewer patients in the tocilizumab group died within 28 days of randomization. 2. Patients allocated tocilizumab were more likely to be discharged from the hospital within 28 days. Evidence Rating Level: 1 (Excellent) Study Rundown: Hypoxic respiratory failure in patients with COVID-19 is associated with systemic inflammation,...
1. Previous infection from SARS-CoV-2 was linked to an 84% lower incidence of reinfection. 2. Median interval between primary infection and reinfection of COVID-19 was greater than 200 days. Evidence Rating Level: 2 (Good) Study Rundown: While it has been suggested that a history of SARS-CoV-2 infection confers protection against subsequent infection,...
1. The AstraZeneca vaccine was 70.4% effective against the B.1.1.7 lineage, compared to 81.5% effective against non-B.1.1.7 lineages. 2. The neutralizing titer of the vaccinated individuals was nine times lower against B.1.1.7 than the non-B.1.1.7 (Victoria) strain in vitro. Evidence Rating Level: 1 (Excellent) Study Rundown: As vaccines are distributed worldwide, concern...
1. Analysis of the two distinct waves of the COVID-19 pandemic in Africa showed a more severe second wave with less stringent public health measures in place. 2. The pandemic had a diverse effect on the different regions of Africa, such as an increased prevalence of cases in the Southern...
1. Hospital readmission and mortality rates were higher in post-COVID patients as compared to matched control groups. 2. More diagnoses of respiratory disease, diabetes, and cardiovascular events were observed in post COVID patients. 3. Older and non-white individuals were at the highest risk for post-COVID complications. Evidence Rating Level: 2 (Good) Study Rundown:...
1. Prior infection with SARS-CoV-2 in the first wave (i.e. before June 2020) was linked to significant protection against reinfection in the second wave in the general population. 2. Protection from repeat SARS-CoV-2 infection was relatively weaker in older populations. Evidence Rating Level: 2 (Good) Study Rundown: Little is known about the...
1. 80% of patients in the azithromycin plus usual care group reported feeling recovered within 28 days, compared to 77% in the usual care group. 2. Safety outcomes were similar in both groups with 1% of patients reporting hospital admission and no deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Treatments that...
1. A cross-sectional sample of residents from Wuhan, China showed low overall seroprevalence (6.92%) of anti-SARS-CoV-2 antibodies in April 2020. 2. Adjusted seroprevalence was lower amongst self-reported asymptomatic individuals than those with symptoms. Evidence Rating Level: 2 (Good) Study Rundown: Over a year after the novel coronavirus SARS-CoV-2 (COVID-19) was characterized as...
1. Overall vaccine efficacy at least 14-days after the second dose was 66.7%. 2. After the initial 21-day exclusion period, there were no hospital admissions for COVID-19 in the ChAdOx1-nCoV-19 group.  Evidence Rating Level: 1 (Excellent) Study Rundown: At the time of this publication, the COVID-19 pandemic continues to burden healthcare systems...